---
title: "BUZZ-Bristol Myers discloses patient death in early-stage autoimmune disease trial; shares fall"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302903119.md"
datetime: "2026-10-23T15:11:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302903119.md)
  - [en](https://longbridge.com/en/news/302903119.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302903119.md)
generator: "portal-rs"
---

# BUZZ-Bristol Myers discloses patient death in early-stage autoimmune disease trial; shares fall

Bristol Myers Squibb (BMY.N) shares fall 2.4% to $61.47

Co says after the data cutoff of an early-stage trial, one patient experienced a fatal event of septic pneumonia

Co was testing its experimental cancer therapy zolacabtagene autoleucel in patients with highly active relapsing multiple sclerosis

Multiple sclerosis is an autoimmune disease that affects the central nervous system

The trial included 66 patients and the therapy’s safety profile was shown to be consistent with previously reported data, co says

Including session moves, stock up 13.9% YTD

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

- [Bristol-Myers Spokesperson Says Grade 5 Event That Was Disclosed As Part Of Data Disclosure At Ms Toronto Occurred After Trial Pause](https://longbridge.com/en/news/302909326.md)
- [Bristol Myers cancer therapy meets main goal in late-stage study](https://longbridge.com/en/news/301581463.md)
- [BUZZ-Bristol Myers rises on positive trial results for cancer and lung disease drugs](https://longbridge.com/en/news/301590676.md)
- [Darling Ingredients (DAR) Could Be 31% Undervalued On Reaffirmed Guidance And Product Launch](https://longbridge.com/en/news/302994330.md)
- [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**